Intra-Cellular Therapies
Market Cap
US$2.7b
Last Updated
2021/01/16 23:12 UTC
Data Sources
Company Financials +
Executive Summary
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and fair value.
Similar Companies
Share Price & News
How has Intra-Cellular Therapies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ITCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ITCI's weekly volatility has decreased from 14% to 8% over the past year.
Market Performance
7 Day Return
2.5%
ITCI
2.2%
US Pharmaceuticals
-1.0%
US Market
1 Year Return
28.7%
ITCI
3.5%
US Pharmaceuticals
19.6%
US Market
Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned 3.7% over the past year.
Return vs Market: ITCI exceeded the US Market which returned 19.6% over the past year.
Shareholder returns
| ITCI | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.5% | 2.2% | -1.0% |
| 30 Day | 19.6% | 4.5% | 2.2% |
| 90 Day | 28.2% | 8.7% | 11.5% |
| 1 Year | 28.7%28.7% | 7.0%3.5% | 22.3%19.6% |
| 3 Year | 87.3%87.3% | 22.8%13.3% | 45.3%35.7% |
| 5 Year | -20.6%-20.6% | 52.5%34.4% | 124.8%99.8% |
Long-Term Price Volatility Vs. Market
How volatile is Intra-Cellular Therapies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Have Insiders Been Selling Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares?1 month ago | Simply Wall St
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In GrowthValuation
Is Intra-Cellular Therapies undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ITCI ($33.78) is trading below our estimate of fair value ($481.16)
Significantly Below Fair Value: ITCI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ITCI is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ITCI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ITCI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ITCI is good value based on its PB Ratio (3.8x) compared to the US Pharmaceuticals industry average (4.4x).
Next Steps
Future Growth
How is Intra-Cellular Therapies forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
48.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITCI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ITCI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ITCI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ITCI's revenue (50.5% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: ITCI's revenue (50.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ITCI is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Intra-Cellular Therapies performed over the past 5 years?
-13.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ITCI is currently unprofitable.
Growing Profit Margin: ITCI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ITCI is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).
Return on Equity
High ROE: ITCI has a negative Return on Equity (-29.16%), as it is currently unprofitable.
Next Steps
Financial Health
How is Intra-Cellular Therapies's financial position?
Financial Position Analysis
Short Term Liabilities: ITCI's short term assets ($744.9M) exceed its short term liabilities ($38.0M).
Long Term Liabilities: ITCI's short term assets ($744.9M) exceed its long term liabilities ($23.9M).
Debt to Equity History and Analysis
Debt Level: ITCI is debt free.
Reducing Debt: ITCI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ITCI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ITCI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Intra-Cellular Therapies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ITCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ITCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ITCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ITCI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ITCI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Sharon Mates (67 yo)
7.42yrs
Tenure
US$4,724,560
Compensation
Dr. Sharon Mates, Ph.D., co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and has been its Chairman, President and Chief Executive Officer since June 2002. Earlier in her career, Dr. Mates...
CEO Compensation Analysis
Compensation vs Market: Sharon's total compensation ($USD4.72M) is about average for companies of similar size in the US market ($USD5.00M).
Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.42yrs | US$4.72m | 1.41% $ 38.3m | |
| Senior VP of Finance | 7.42yrs | US$2.19m | 0% $ 0 | |
| Executive VP | 6.5yrs | US$2.34m | 0% $ 0 | |
| EVP & Chief Commercial Officer | 2.25yrs | US$2.51m | 0.049% $ 1.3m | |
| Senior VP & Chief Scientific Officer | 5.17yrs | US$2.13m | no data | |
| Vice President of Corporate Communications & Investor Relations | 6.83yrs | US$1.38m | no data | |
| Senior VP & Chief Compliance Officer | 1.5yrs | no data | no data | |
| Senior VP & Chief Medical Officer | 2.42yrs | no data | 0.022% $ 590.6k | |
| Senior VP & Head of Regulatory Affairs | 2.33yrs | no data | no data | |
| Senior VP of Market Access | 1.83yrs | no data | no data |
3.8yrs
Average Tenure
58yo
Average Age
Experienced Management: ITCI's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.42yrs | US$4.72m | 1.41% $ 38.3m | |
| Independent Director | 7yrs | US$240.74k | 0.077% $ 2.1m | |
| Lead Independent Director | no data | US$252.74k | 0.010% $ 272.4k | |
| Independent Director | 7.42yrs | US$242.77k | 0.084% $ 2.3m | |
| Independent Director | 7.42yrs | US$240.74k | 2.4% $ 65.0m | |
| Independent Director & Member of Scientific Advisory Board | no data | US$237.72k | 0.13% $ 3.6m | |
| Chairman of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
7.4yrs
Average Tenure
67yo
Average Age
Experienced Board: ITCI's board of directors are considered experienced (7.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ITCI insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.5%.
Top Shareholders
Company Information
Intra-Cellular Therapies, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Intra-Cellular Therapies, Inc.
- Ticker: ITCI
- Exchange: NasdaqGS
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.708b
- Shares outstanding: 80.16m
- Website: https://www.intracellulartherapies.com
Number of Employees
Location
- Intra-Cellular Therapies, Inc.
- 430 East 29th Street
- Suite 900
- New York
- New York
- 10016
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ITCI | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Dec 2013 |
| 23I | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Dec 2013 |
Biography
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in t...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/16 23:12 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.